Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial

Sluis, Wouter M.; de Jonge, Jeroen C.; Reinink, Hendrik; Woodhouse, Lisa J.; Westendorp, Willeke F.; Bath, Philip M.; van de Beek, Diederik; van der Worp, H. Bart; for the PRECIOUS Investigators

Abstract

BACKGROUND:
A randomized trial suggested that treatment with metoclopramide reduces the risk of pneumonia in patients with acute stroke and a nasogastric tube. We assessed whether this finding could be replicated in a post hoc analysis of the randomized PRECIOUS trial (Prevention of Complications to Improve Outcome in Elderly Patients With Acute Stroke).
METHODS:
PRECIOUS was an international, 3×2 partial-factorial, randomized controlled, open-label clinical trial with blinded outcome assessment assessing preventive treatment with metoclopramide, paracetamol, and ceftriaxone in patients aged ≥66 years with acute ischemic stroke or intracerebral hemorrhage and a National Institutes of Health Stroke Scale score ≥6. In the present study, we analyzed patients who had a nasogastric tube within 24 hours after randomization. Patients who were allocated to metoclopramide (10 mg TID) were compared with patients who were not. Treatment was started within 24 hours after symptom onset and continued for 4 days or until discharge if earlier. The primary outcome was pneumonia in the first week after stroke. The score on the modified Rankin Scale after 90 days was a secondary outcome and analyzed with ordinal logistic regression.
RESULTS:
From April 2016 through June 2022, a total of 1493 patients were enrolled with 1376 included in this analysis, of whom 1185 (86%) had ischemic stroke and 191 (14%) had intracerebral hemorrhage. The first day after randomization, 329 (23.9%) patients had a nasogastric tube, of whom 156 were allocated to metoclopramide and 173 to standard care. Metoclopramide was not associated with a reduction of pneumonia (41.0% versus 35.8%; adjusted odds ratio, 1.35 [95% CI, 0.79–2.30]) or with poor functional outcome (adjusted odds ratio, 1.07 [95% CI, 0.71–1.61]).
CONCLUSIONS:
In patients with stroke who had a nasogastric tube shortly after stroke onset, metoclopramide for 4 days did not reduce pneumonia or have an effect on the functional outcome.

Citation

Sluis, W. M., de Jonge, J. C., Reinink, H., Woodhouse, L. J., Westendorp, W. F., Bath, P. M., van de Beek, D., van der Worp, H. B., & for the PRECIOUS Investigators. (2024). Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial. Stroke, 55(10), 2402-2408. https://doi.org/10.1161/strokeaha.124.047582

• Journal Article Type: Article
• Acceptance Date: Jul 12, 2024
• Online Publication Date: Aug 12, 2024
• Publication Date: 2024-10
• Deposit Date: Sep 11, 2024
• Publicly Available Date: Sep 11, 2024
• Journal: Stroke
• Print ISSN: 0039-2499
• Electronic ISSN: 1524-4628
• Publisher: American Heart Association
• Peer Reviewed: Peer Reviewed
• Volume: 55
• Issue: 10
• Pages: 2402-2408
• DOI: https://doi.org/10.1161/strokeaha.124.047582
• Public URL: https://nottingham-repository.worktribe.com/output/38383510
• Publisher URL: https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.047582